LT2706982T - Intranazalinės farmacinės vaisto formos, apimančios naloksoną - Google Patents

Intranazalinės farmacinės vaisto formos, apimančios naloksoną

Info

Publication number
LT2706982T
LT2706982T LTEP12721507.7T LT12721507T LT2706982T LT 2706982 T LT2706982 T LT 2706982T LT 12721507 T LT12721507 T LT 12721507T LT 2706982 T LT2706982 T LT 2706982T
Authority
LT
Lithuania
Prior art keywords
naloxone
dosage forms
pharmaceutical dosage
intranasal pharmaceutical
intranasal
Prior art date
Application number
LTEP12721507.7T
Other languages
English (en)
Inventor
John STRANG
Alexander Oksche
Stephen Harris
Kevin Smith
Lucie Helene Jeanne MOTTIER
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2706982(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of LT2706982T publication Critical patent/LT2706982T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP12721507.7T 2011-05-13 2012-05-11 Intranazalinės farmacinės vaisto formos, apimančios naloksoną LT2706982T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166076 2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Publications (1)

Publication Number Publication Date
LT2706982T true LT2706982T (lt) 2018-05-25

Family

ID=44658496

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12721507.7T LT2706982T (lt) 2011-05-13 2012-05-11 Intranazalinės farmacinės vaisto formos, apimančios naloksoną

Country Status (37)

Country Link
US (8) US20150018379A1 (lt)
EP (2) EP3320893A1 (lt)
JP (3) JP6110367B2 (lt)
KR (2) KR101873174B1 (lt)
CN (2) CN107260672A (lt)
AR (1) AR086391A1 (lt)
AT (1) AT16553U1 (lt)
AU (2) AU2012257785B2 (lt)
BR (1) BR112013029126A2 (lt)
CA (1) CA2835940C (lt)
CO (1) CO6821959A2 (lt)
CY (1) CY1120399T1 (lt)
DE (1) DE202012013606U1 (lt)
DK (2) DK2706982T4 (lt)
ES (1) ES2661838T5 (lt)
HK (1) HK1255428A1 (lt)
HR (1) HRP20180233T1 (lt)
HU (1) HUE036465T2 (lt)
IL (1) IL229409B (lt)
LT (1) LT2706982T (lt)
ME (1) ME02958B (lt)
MX (1) MX354249B (lt)
MY (1) MY194947A (lt)
NO (1) NO2706982T3 (lt)
PH (2) PH12013502313A1 (lt)
PL (1) PL2706982T3 (lt)
PT (1) PT2706982T (lt)
RS (1) RS57054B1 (lt)
RU (2) RU2657441C1 (lt)
SG (1) SG194927A1 (lt)
SI (1) SI2706982T1 (lt)
SM (1) SMT201800105T1 (lt)
TR (1) TR201802716T4 (lt)
TW (1) TWI486161B (lt)
UA (1) UA110974C2 (lt)
WO (1) WO2012156317A2 (lt)
ZA (1) ZA201308280B (lt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
DK2706982T4 (da) * 2011-05-13 2021-05-10 Euro Celtique Sa Intranasale farmaceutiske dosisformer omfattende naloxon
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
RU2020112530A (ru) 2014-03-14 2021-07-21 ОПИАНТ ФАРМАСЮТИКАЛС, Инк. Назальные готовые лекарственные формы и способы их применения
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007729A1 (en) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US11559483B2 (en) * 2015-07-10 2023-01-24 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
CA2950687C (en) * 2015-09-17 2023-02-28 Adapt Pharma Limited Nasal drug products and methods of their use
US20190209464A1 (en) * 2016-06-24 2019-07-11 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of alcohol use disorder
EP3500261A4 (en) * 2016-08-17 2020-05-06 Hikma Pharmaceuticals USA Inc. LIQUID NALOXONE SPRAYING
EP3946547B1 (en) * 2019-03-26 2026-03-25 Pinova Therapeutics Inc. Devices and methods for delivering pharmaceutical compositions
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
WO2021158957A1 (en) 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US20230201369A1 (en) * 2020-04-29 2023-06-29 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
SMT202200411T1 (it) 2020-05-18 2022-11-18 Orexo Ab Nuova composizione farmaceutica per il rilascio controllato di farmaci
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
MX2024001659A (es) 2021-08-04 2024-06-26 Indivior Inc Composiciones y métodos para el tratamiento de la sobredosis por opioides.
AU2022395920A1 (en) 2021-11-25 2024-05-30 Orexo Ab Pharmaceutical composition comprising adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
JP2003501467A (ja) 1999-06-16 2003-01-14 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 鼻内モルヒネを含む医薬用製剤および方法
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
DE60133203T3 (de) * 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1535615A4 (en) 2002-07-11 2010-03-31 Taiho Pharmaceutical Co Ltd COMPOSITION FOR THE NASAL ABSORPTION
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
CN1575795A (zh) * 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
WO2006051448A2 (en) * 2004-11-09 2006-05-18 Koninklijke Philips Electronics N.V. Array of spatial light modulators and method of production of a spatial light modulator device
ZA200704869B (en) * 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RU2344822C2 (ru) * 2006-04-05 2009-01-27 Алексей Валентинович Надеждин Способ лечения героиновой наркомании
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
CN106389330A (zh) * 2007-01-19 2017-02-15 哈南亚有限公司 用于递送治疗剂的方法和组合物
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
DK2706982T4 (da) * 2011-05-13 2021-05-10 Euro Celtique Sa Intranasale farmaceutiske dosisformer omfattende naloxon
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
RU2020112530A (ru) 2014-03-14 2021-07-21 ОПИАНТ ФАРМАСЮТИКАЛС, Инк. Назальные готовые лекарственные формы и способы их применения
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Also Published As

Publication number Publication date
HK1255428A1 (en) 2019-08-16
PH12016501342B1 (en) 2018-06-11
EP3320893A1 (en) 2018-05-16
US20170231904A1 (en) 2017-08-17
IL229409B (en) 2020-10-29
DE202012013606U1 (de) 2018-04-18
IL229409A0 (en) 2014-01-30
ME02958B (me) 2018-07-20
UA110974C2 (uk) 2016-03-10
TR201802716T4 (tr) 2018-03-21
US20150126540A1 (en) 2015-05-07
EP2706982B1 (en) 2018-01-03
US20240082149A1 (en) 2024-03-14
BR112013029126A2 (pt) 2017-02-07
US11806428B2 (en) 2023-11-07
NO2706982T3 (lt) 2018-06-02
PT2706982T (pt) 2018-03-08
EP2706982A2 (en) 2014-03-19
AU2012257785A1 (en) 2013-11-28
AU2016204880A1 (en) 2016-07-28
EP2706982B2 (en) 2021-03-10
JP6110367B2 (ja) 2017-04-05
CN107260672A (zh) 2017-10-20
SG194927A1 (en) 2013-12-30
DK201800034U1 (da) 2018-05-25
MY194947A (en) 2022-12-27
US20210338574A1 (en) 2021-11-04
MX2013013276A (es) 2014-08-07
PH12013502313A1 (en) 2022-04-08
US20260108456A1 (en) 2026-04-23
US20150018379A1 (en) 2015-01-15
DK2706982T4 (da) 2021-05-10
PH12016501342A1 (en) 2018-06-11
WO2012156317A3 (en) 2013-05-10
US11020343B2 (en) 2021-06-01
TWI486161B (zh) 2015-06-01
JP2014513683A (ja) 2014-06-05
RU2587051C2 (ru) 2016-06-10
NZ617442A (en) 2015-03-27
CN103764119A (zh) 2014-04-30
RS57054B1 (sr) 2018-05-31
AR086391A1 (es) 2013-12-11
US20190374464A1 (en) 2019-12-12
ES2661838T3 (es) 2018-04-04
CA2835940A1 (en) 2012-11-22
KR101873174B1 (ko) 2018-06-29
DK2706982T3 (en) 2018-03-12
CY1120399T1 (el) 2019-07-10
TW201311244A (zh) 2013-03-16
ES2661838T5 (es) 2021-11-18
JP2016128453A (ja) 2016-07-14
CO6821959A2 (es) 2013-12-31
KR101698182B1 (ko) 2017-01-19
RU2013155479A (ru) 2015-06-20
KR20140007482A (ko) 2014-01-17
AU2016204880B2 (en) 2017-11-23
US20170304192A1 (en) 2017-10-26
HRP20180233T1 (hr) 2018-06-01
NZ705933A (en) 2016-07-29
AU2012257785B2 (en) 2016-04-14
MX354249B (es) 2018-02-20
HUE036465T2 (hu) 2018-07-30
KR20170010078A (ko) 2017-01-25
JP2018150336A (ja) 2018-09-27
SI2706982T1 (en) 2018-05-31
US12458591B2 (en) 2025-11-04
AT16553U1 (de) 2020-01-15
SMT201800105T1 (it) 2018-05-02
CA2835940C (en) 2020-08-04
RU2657441C1 (ru) 2018-06-13
PL2706982T3 (pl) 2018-07-31
WO2012156317A2 (en) 2012-11-22
ZA201308280B (en) 2014-07-30

Similar Documents

Publication Publication Date Title
IL229409A0 (en) Intravenous pharmaceutical dosage forms containing naloxone
SI2776416T1 (sl) Farmacevtske spojine
LT4067496T (lt) Adam6 pelės
SG10201604667YA (en) Pharmaceutical preparation
IL232305A0 (en) pharmaceutical preparations
GB201323133D0 (en) Tablet dispenser
GB2525835B (en) Pharmaceutical agent
GB201119799D0 (en) Pharmaceutical compounds
ZA201403832B (en) Pharmaceutical compounds
GB201105298D0 (en) Pharmaceutical preparation
GB201118876D0 (en) Pharmaceutical compounds
PL2768485T3 (pl) Nanozawiesina farmaceutyczna
GB201113163D0 (en) Pharmaceutical compounds
EP2712348A4 (en) DISTRIBUTOR AND METHODS
GB201218012D0 (en) Dosage forms
GB201118334D0 (en) Novel dosage form
PL2691119T3 (pl) Preparat farmaceutyczny
GB201119796D0 (en) Pharmaceutical comopounds
GB201108234D0 (en) Pharmaceutical agent
GB201120735D0 (en) New pharmaceutical uses
GB201105026D0 (en) Pharmaceutical compounds
GB201118874D0 (en) Pharmaceutical compounds
GB201118875D0 (en) Pharmaceutical compounds
GB201117359D0 (en) Pharmaceutical compounds
GB201113730D0 (en) Solid dosage form